IVERIC bio

IVERIC bio FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of IVERIC bio (ISEE) as of Oct 22, 2026 is 93.61 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 86.59 % — a change of 8.10% (higher).

FCF Conversion

93.61 %

YoY

8.10%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of IVERIC bio is 2022 93.61 % . FCF Conversion Rate (FCF/EBITDA) of IVERIC bio was 2021 86.59 % . It decreases by 8.10% higher compared to the previous year.

The IVERIC bio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
76.76 USD
Jan 1, 2016
56.44 USD
Jan 1, 2017
-106.67 USD
Jan 1, 2018
-67.01 USD
Jan 1, 2019
83.00 USD
Jan 1, 2020
78.60 USD
Jan 1, 2021
86.59 USD
Jan 1, 2022
93.61 USD
The IVERIC bio FCF Conversion history
YEARFCF ConversionYoY
93.61 %+8.10%
86.59 %+10.16%
78.60 %-5.29%
83.00 %-223.86%
-67.01 %-37.18%
-106.67 %-288.99%
56.44 %-26.47%
76.76 %-168.87%
-111.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IVERIC bio Stock analysis

What does IVERIC bio do? Iveric Bio Inc is a leading biopharmaceutical company specializing in the discovery and development of therapy options for eye diseases. The company was originally founded in 1989 as Ophthotech Corp. and is headquartered in New York City. Iveric Bio Inc aims to develop innovative treatments for eye diseases that can improve the lives of millions of people. The eye diseases that Iveric Bio Inc is fighting range from retinal diseases to degenerative eye diseases. Iveric Bio Inc has a strong business model, focusing on innovation to develop new treatment methods. The company invests in research and development to create a solid pipeline of new therapies, while also closely collaborating with the medical community to ensure that the therapies meet the needs of patients and doctors. Iveric Bio Inc's therapy options are focused on treating eye diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal diseases. Iveric Bio Inc also focuses on preserving vision and improving the quality of life for people with glaucoma and other eye diseases. Iveric Bio Inc's portfolio currently includes two main products: Zimura and GATHER1. Zimura is a potentially groundbreaking medication developed for the treatment of dry age-related macular degeneration (AMD). It is currently being studied in late-stage clinical trials and could play an important role in the future of AMD treatment. GATHER1, the other main product of Iveric Bio Inc, is a clinical drug candidate developed for the treatment of geographic atrophy (GA). GA is an advanced form of dry AMD associated with the destruction of cells in the retina and a loss of vision. GATHER1 has been deemed promising in Phase II trials and is currently being tested in Phase III trials. Overall, Iveric Bio Inc has an excellent track record in the development of therapy options for eye diseases. The company has a wide range of treatment possibilities in the pipeline aimed at meeting the need for effective therapies for various eye diseases. Additionally, Iveric Bio Inc works closely with the medical community and other biopharmaceutical companies to share the latest research findings and advance the treatment of eye diseases. Overall, Iveric Bio Inc is an emerging biopharmaceutical company with a strong focus on research and development. The company has a strong business model and a robust pipeline of therapy options aimed at improving eye health and the quality of life for millions of people. IVERIC bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IVERIC bio stock

FCF Conversion Rate (FCF/EBITDA) of IVERIC bio is 93.61 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of IVERIC bio changed from 86.59 % to 93.61 %, representing a 8.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) IVERIC bio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s IVERIC bio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IVERIC bio

All Key Metrics — IVERIC bio